

BIOSPECIFICS TECHNOLOGIES CORP

Form 8-K

July 23, 2009

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): July 22, 2009

BIOSPECIFICS TECHNOLOGIES CORP.  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction  
Of Incorporation)

**0-19879**  
(Commission File Number)

**11-3054851**  
(I.R.S. Employer  
Identification No.)

**35 Wilbur Street**  
**Lynbrook, NY 11563**  
(Address of Principal Executive Office) (Zip Code)

**516.593.7000**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Introductory Comment

Throughout this Current Report on Form 8-K, the terms "we," "us," "our" and "Company" refer to BioSpecifics Technologies Corp.

ITEM 7.01

REGULATION FD DISCLOSURE

Our President, Thomas L. Wegman, will present to investors at the upcoming CapStone Investments Third Annual Small-Cap Investor Conference on Wednesday, July 29, 2009 in Milwaukee, Wisconsin. A copy of the presentation materials is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. A press release regarding the announcement is attached hereto as Exhibit 99.2.

ITEM 9.01.

FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Exhibit No.	Description
----------------	-------------

<u>99.1</u>	<u>Presentation materials to be used by Thomas L. Wegman, the Company's President, on July 29, 2009</u>
-------------	---

<u>99.2</u>	<u>Press release dated July 22, 2009</u>
-------------	--

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, each registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: July 22, 2009

BIOSPECIFICS TECHNOLOGIES CORP.  
(Registrant)

/s/ Thomas L. Wegman  
Thomas L. Wegman  
President

---

**EXHIBIT INDEX**

---